After Altimmune reported Q4 results and updates, Piper Sandler analyst Yasmeen Rahimi noted that management emphasized on the earnings call that partners appreciated pemvidutide’s comprehensive and differentiated profile with potential in obesity, dyslipidemia, and NASH in ongoing discussions. The firm, which continues to be bullish on Altimmune, keeps an Overweight rating and $25 price target on the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALT:
- Options Volatility and Implied Earnings Moves Today, March 27, 2024
- Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results
- Options Volatility and Implied Earnings Moves This Week, March 26 – March 28, 2024
- ALT Upcoming Earnings Report: What to Expect?
- Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024
